Company: HCTI
Filing Date: 2025-11-25
Form Type: 424B3
Source: 0001213900-25-114840
Chunk: 19

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-25
Form: 424B3
Chunk 19
---
 such an event, the trading price of our common stock could decline and you could lose part or all of your investment.

Risks Related to the Resale of the Shares and Ownership of Shares of Our Common Stock

The Selling Stockholders may choose to sell the Shares at prices below the current market price.

The Selling Stockholders are not restricted as
to the prices at which they may sell or otherwise dispose of the Shares covered by this prospectus. Sales or other dispositions of the
Shares below the then-current market prices could adversely affect the market price of our Common Stock.

A large number of shares of Common Stock may be sold in the market following this offering, which may significantly depress the market price of our Common Stock.

The Shares sold in the offering will be freely
tradable without restriction or further registration under the Securities Act. As a result, a substantial number of shares of Common Stock
may be sold in the public market following this offering. If there are significantly more shares of Common Stock offered for sale than
buyers are willing to purchase, then the market price of our Common Stock may decline to a market price at which buyers are willing to
purchase the offered Common Stock and sellers remain willing to sell Common Stock.

We will have broad discretion as to the proceeds that we receive from the cash exercise by any holder of the Warrants, and we may not use the proceeds effectively.

We will not receive any of the proceeds from the sale of the Shares by the Selling Stockholders pursuant to this prospectus. We may receive up to approximately $4.37 million in aggregate gross proceeds from cash exercises of the Common Warrants, based on the current per share exercise price of $3.00 of the Common Warrants. If the exercise price is adjusted downwards pursuant to the terms of anti-dilution features of such warrants or certain cashless exercise provisions, we will receive less aggregate gross proceeds if any of the Common Warrants are exercised at such lower price. To the extent that we receive such proceeds, we intend to use the net proceeds from cash exercises of the Common Warrants for working capital, capital expenditures, and other general corporate purposes. We have considerable discretion in the application of such proceeds. You will not have the opportunity, as part of your investment decision, to assess whether such proceeds are being used in a manner agreeable to you. You must rely on our judgment regarding the application of the net proceeds from cash exercises of the Common Warrants, which may be used for corporate purposes that do not improve our profitability or increase